MichaelParaMD

PubMed

• 16 citations
  A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy.
  Deborah K McMahon, Lu Zheng, Joshua C Cyktor, Evgenia Aga, Bernard J Macatangay, Catherine Godfrey, Michael Para, Ronald T Mitsuyasu, Joseph Hesselgesser, Joan Dragavo...> ;The Journal of Infectious Diseases. 2021 Aug 16
• 33 citations
  Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
  Sharon A. Riddler, Michael F. Para, Constance A. Benson, Anthony Mills, Moti Ramgopal, Edwin DeJesus, Cynthia Brinson, Joshua C. Cyktor, Jana L. Jacobs, Dianna Koontz,...> ;Clinical Infectious Diseases. 2021 Jun 1
• 4 citations
  A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 ex...
  Deborah McMahon, Lu Zheng, Joshua C. Cyktor, Evgenia Aga, Bernard J.C. Macatangay, Catherine Godfrey, Michael F. Para, Ronald T. Mitsuyasu, Joseph Hesselgesser, Joan D...> ;The Journal of Infectious Diseases. 2020 Dec 22
• 11 citations
  Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.
  You Jeong Park, Behzad Etemad, Hayat Ahmed, Vivek Naranbhai, Evgenia Aga, Ronald J. Bosch, John W. Mellors, Daniel R. Kuritzkes, Michael F. Para, Rajesh T. Gandhi, Mar...> ;Pathogens & Immunity. 2017 Nov 27
• 28 citations
  Taking Control: The Efficacy and Durability of a Peer-Led Uncertainty Management Intervention for People Recently Diagnosed With HIV
  Dale E. Brashers, Erin D. Basinger, Lance S. Rintamaki, John P. Caughlin, Michael F. Para> ;Health Communication. 2017 Jan 2
• 16 citations
  Brief Report: Relationship Among Viral Load Outcomes in Hiv Treatment Interruption Trials
  Evgenia Aga, Ronald J. Bosch, John W. Mellors, Daniel R. Kuritzkes, Michael Para, Rajesh T. Gandhi, Jonathan Z. Li> ;Journal of Acquired Immune Deficiency Syndromes. 2016 Jul 1
• StudySearch: a web-based application for posting and searching clinical research studies
  Blair Gonsenhauser, Rose Hallarn, Daniel Carpenter, Michael F. Para, Carson Reider> ;Journal of Investigative Medicine. 2016 Jan 29
• 217 citations
  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
  Jonathan Z. Li, Behzad Etemad, Hayat Ahmed, Evgenia Aga, Ronald J. Bosch, John W. Mellors, Daniel R. Kuritzkes, Michael M. Lederman, Michael F. Para, Rajesh T. Gandhi> ;AIDS. 2015 Nov 1
• 19 citations
  Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.
  Anthony R. Cillo, Supriya Krishnan, Deborah McMahon, Ronald T. Mitsuyasu, Michael F. Para, John W. Mellors> ;Plos One. 2014 Mar 17
• 8 citations
  The Design of Single-Arm Clinical Trials of Combination Antiretroviral Regimens for Treatment-Naive HIV-Infected Patients
  Lu Zheng, Susan L. Rosenkranz, Babafemi Taiwo, Michael F. Para, Joseph J. Eron, Michael Hughes> ;AIDS Research and Human Retroviruses. 2013 Apr 5
• 95 citations
  Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Plos Medicine. 2012 Aug 14
• 31 citations
  Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomize...
  Mark T. Nelson, Gerardo Amaya, Nathan Clumeck, Clovis Arns da Cunha, Dushyantha Jayaweera, Patrice Junod, Taisheng Li, Pablo Tebas, Marita Stevens, Annemie Buelens, Si...> ;The Journal of Antimicrobial Chemotherapy. 2012 Aug 1
• 27 citations
  Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients
  Danxin Wang, Amanda Curtis, Audrey C. Papp, Susan L. Koletar, Michael F. Para> ;BMC Medical Genomics. 2012 Jul 23
• 7 citations
  HIV and asthma, is there an association?
  Jessica A. Kynyk, Jonathan P. Parsons, Michael F. Para, Susan L. Koletar, Philip T. Diaz, John G. Mastronarde> ;Respiratory Medicine. 2012 Apr 1
• 35 citations
  Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.
  Danxin Wang, Michael F. Para, Susan L. Koletar, Wolfgang Sadee> ;Pharmacogenetics and Genomics. 2011 Oct 1
• [Cavernous haemangioma of the right atrium].
  Para, M., Lairez, O., Guilbeau-Frugier, C., Marcheix, B.> ;Ann Cardiol Angeiol (Paris). 2011 Jun
• 7 citations
  Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.
  Michael F. Para, Jeff Schouten, Susan L. Rosenkranz, Song Yu, David B. Weiner, Pablo Tebas, C. Jo White, Dominic N. Reeds, Juan J.L. Lertora, Kristine B. Patterson, Er...> ;Journal of Acquired Immune Deficiency Syndromes. 2010 Apr 1
• 60 citations
  No Evidence for Decay of the Latent Reservoir in HIV-1—Infected Patients Receiving Intensive Enfuvirtide-Containing Antiretroviral Therapy
  Rajesh T. Gandhi, Ronald J. Bosch, Evgenia Aga, Mary Albrecht, Lisa M. Demeter, Carrie Dykes, Barbara Bastow, Michael F. Para, Jun Lai, Robert F. Siliciano, Janet D. S...> ;The Journal of Infectious Diseases. 2010 Jan 15
• 4 citations
  HIV testing outside of the study among men who have sex with men participating in an HIV vaccine efficacy trial.
  Deborah A. Gust, Ryan E. Wiegand, Michael F. Para, Robert T. Chen, Brad Bartholow> ;Journal of Acquired Immune Deficiency Syndromes. 2009 Oct 1
• 58 citations
  Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
  Jacob Lalezari, Gopal Yadavalli, Michael F. Para, Gary Richmond, Edwin DeJesus, Stephen J. Brown, Wendy Cai, Cecil Chen, John Zhong, Lu Anne Novello, Michael M. Lederm...> ;The Journal of Infectious Diseases. 2008 Mar 1
• 5 citations
  Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers
  Qing Ma, Alan Forrest, Susan L. Rosenkranz, Michael F. Para, Kevin E. Yarasheski, Richard C. Reichman, Gene D. Morse, Actg A Protocol Team, Daids, Nih> ;Biopharmaceutics & Drug Disposition. 2008 Jan 1
• 9 citations
  Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis
  Susan L. Rosenkranz, Kevin E. Yarasheski, Michael F. Para, Richard C. Reichman, Gene D. Morse> ;Metabolic Syndrome and Related Disorders. 2007 Jun 1
• 18 citations
  Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks
  Olanrewaju O. Okusanya, Alan Forrest, Robin DiFrancesco, Sanela Bilic, Susan L. Rosenkranz, Michael F. Para, Elizabeth Adams, Kevin E. Yarasheski, Richard C. Reichman,...> ;Antimicrobial Agents and Chemotherapy. 2007 May 1
• 7 citations
  Partner-specific sexual behavioral differences between phase 3 HIV vaccine efficacy trial participants and controls: Project VISION.
  William L. H. Whittington, Martina Morris, Susan Buchbinder, David J. McKirnan, Kenneth H. Mayer, Michael F. Para, Bradford N. Bartholow, Connie Celum> ;Journal of Acquired Immune Deficiency Syndromes. 2006 Oct 1
• 20 citations
  Third-trimester maternal toxicity with nevirapine use in pregnancy.
  Saju Joy, Ming Poi, Laura Hughes, Michael T. Brady, Susan L. Koletar, Michael F. Para, Patty Fan-Havard> ;Obstetrics and Gynecology. 2005 Nov 1
• Join now to see all

Journal Articles

• Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials  
  Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZ., J Acquir Immune Defic Syndr, 1/20/2016
• The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption  
  Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT, AIDS, 1/1/2016
• Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257  
  Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Ke..., Clin Infect Dis, 1/15/2015
• Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy  
  Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW, PLoS One, 1/17/2014
• Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients  
  Wang  Danxin, Curtis  Amanda, Papp C Audrey, Koletar L Susan, Para F Michael, BMC Medical Genomics, 1/1/2013
• HIV and Asthma, Is there an Association  
  Kynyk JA, Parsons JP,1, Para MF, Susan L Koletar SL, Diaz PT, Mastronarde JG, Respir Med, 1/1/2012
• No evidence for decay in the latent reservoir in HIV infects patients receiving intensive enfuvirdtide- containing antiretroviral therapy  
  Gandhi R, Bosch RJ, Aga E, Albrecht M, Adams E, Demeter L, Dykes C, Bastow B, Para, M, Si;iciano R, Siliciano J, Eron J, for the ACTG 5173 Team, 1/1/2010
• Pharmacokinetic Interactions between efavirenz and dual protease inhibitors in healthy volunteers  
  Ma Qing, Forrest A, Rosenkranz S, Para MF, Yarasheski K, Reichman R, Morse G, ACTG 5043 team, Biopharmaceutics and Drug Disposition Biopharm Drug Dispos, 1/1/2008
• Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peak  
  Okusanya O, Forrest A, DiFrancesco R, Balic S, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD, Antimicro Agent Chemo, 1/1/2007
• Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic- pharmacodynamic analysis  
  Rosenkranz SL,Yarasheski KE, Para MF, Reichman R, Morse GD, and the ACTG 5043 Protocol Team, Metabolic Syndrome and Related Conditions, 1/1/2007
• HIV Sexual Risk Behavior over 36-Months of Follow-up in the World’s First HIV Vaccine Efficacy Trial  
  Bartholow, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, McKirnan DJ, Creticos C, Orozco-Cronin P, Popovic V, and Mastro TD, for the..., BN J Acquir Immune Defic Syndr, 1/1/2005
• Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals  
  Smith PF, DiCenzo R, Forrest A, Shelton M, Friedland G, Michael F. Para MF, Pollard R, Fischl M, DiFrancesco R, Morse GD, Clinical Pharmacokinet, 1/1/2005
• Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection  
  Gurwith,M, Gilbert P, Berman P, Flynn, N, Forthal D, Harro C, Heyward, W, Hudgens M, Judson F, Mayer K, Metch B, Para, MF, PopovicV, Self, S., and Francis DP, for th..., J Infect Dis, 1/1/2005
• Amprenavir and Efavirenz Pharmacokinetics Before and After the Addition of Nelfinavir, Indinavir, Ritonavir or Saquinavir Antimicrob  
  Morse GD, Rosenkranz S, Para MF, Segal Y DiFrancesco R Adams E Brizz B, Yarasheski K, Reichman R, and the ACTG 5043 Protocol Team, Agents Chemother, 1/1/2005
• Third Trimester Maternal Toxicity with Nevirapine use in Pregnancy  
  Joy S, Poi M, Hughes L, Brady M, Koletar, SL, Para MF, and Fan-Havard, P, Obstet and Gynecol, 1/1/2005
• Drug rash, eosinophilia, systemic syndrome and renal toxicity with nevirapine-containing regimen in a pregnant patient with HIV  
  Knudtson E, Para M, Boswell H, and Fan-Havard P, Obstet Gynecol, 1/1/2003
• Virologic efficacy of nelfinavir and/or efavirenz with new nucleoside therapy in HIV-infected individuals with prior nucleoside analog exposure  
  Albrecht MA, Bosch RJ, Dehlinger M, Katzenstein DA, Liou SH, Eron J, Para MF, Valdez H, Kessler H, Hammer SM, N Engl J Med, 1/9/2001
• Qualitative and Quantitative PCR Measures of CMV in Patients with Advanced HIV Infection Requiring Transfusion  
  Para MF, Kalish LA, Collier AC, Pollard R, Kumar P, Wallach F, Mintz L, and Drew WL for the VATS Study Group, J Acquire Immun Defic Syndrom, 1/1/2001
• Aerobic exercise training: Effects on parameters associated with fatigue, dyspnea, weight and body composition in HIV-1 infected adults  
  Smith BA, Neidig JL, Nickel JT, Mitchell GL, Para MF, Fass.RJ, AIDS, 1/1/2001
• Correlates of change in CMV viremia in Patients with Advanced HIV Infection Requiring Transfusion  
  Para MF, Kalish LA, Collier AC, Murphy EL, Drew WL, J Infect Dis, 1/1/2001
• Delavirdine susceptiblities and associated RT mutations in HIV-1 isolates from patients in a Phase I/II trail of Delavirdine monotherapy (ACTG 260)  
  L. M. Demeter, R.W. Shafer, P.M. Meehan, J. Holden-Wiltse, M.A. Fischl, W.W. Freimuth, M.F. Para, R.C. Reichman, Antimicro Agent Chemo, 1/1/2000
• Concentration-targeted phase I trials of atevirdine mesylate: in patients with HIV  
  Morse G, Reichman RC, Fischl M, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D, and the ACTG 187 and 199 Study Teams, Antiviral Res, 1/1/2000
• Reduced Toxicity with the Gradual Initiation of Trimethoprim-Sulfamethoxazole as Primary Prophylaxis for Pneumocystis carinii Pneumonia (PCP) - ACTG 268  
  Para, MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black J, and the ACTG 268 Study Team, J Acquire Immun Defic Syndrom, 1/1/2000
• Evaluating the relationship between drug susceptibility phenotype and protease genotype among HIV infected patients treated with protease inhibitors  
  Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes A, Para MF, Boucher CAB, J Infect Dis, 1/1/2000
• Baseline HIV-1 Phenotype, Genotype and RNA Response after Switching from Long Term Saquinavir to Indinavir or Saquinavir Soft Gelatin Capsule in ACTG 333  
  Para MF, Glidden DV, Coombs RW, Collier AC, Condra JH, Craig C, Bassett R, Leavitt, Synder S, McAuliffe V, Boucher C. for the AIDS Clinical Trials Group Protocol 333 Team, J Infect Dis, 1/1/2000
• Join now to see all

Books/Book Chapters

• Antimicrobial Therapy and Vaccines Volume II Antimicrobial Agents 
  Chapter: Nonnucleoside Analogue Reverse Transcriptase Inhibitors 
  Fletcher C, Swindells S, Para MEditors: Yu V, Edwards G, McKinnon P, Peloquin, Morse, Potoski.2005
• Principals of Infection and Resistance 
  Chapter: Principals of Infection and Resistance 
  Koletar SL and Para MFEditors: Mortensen RF, Krier J.Harper and Rowe Publishers, Philadelphia, PA1990
• Internal Medicine - Case studies 
  Chapter: A man with shortness of breath, weight loss and night sweats 
  Para MFEditors: Bowen & Mazzaferri.Plenum Publishing, New York, NY1989
• Mitral Valve Prolapse and Mitral Valve Prolapse Syndrome 
  Chapter: Mitral Valve Prolapse and Infective Endocarditis 
  Koletar SL and Para MFEditors: Boudoulas, H. and Wooley, C.Futura Publishing Co., Mount Kisco, N.Y.1988
• Sexually Trans­mitted Diseases 
  Chapter: Chapter 6: Genital ulcer syndrome 
  Para MF and Baird IEditors: R. Prior and V. Spagna.Marcel Dekker, New York, NY1985
• Legionella, Proceedings of the Second Inter­national Symposium on Legionella 
  Chapter: Production of monoclonal anti­bodies to Legionella pneumophila and the relationship of monoclonal antibody binding to plasmid content 
  Para MF, Plouffe JF and Maher WEEditors: Thornsberry C., Balows A, Feeley JC, Jakubowski W.ASM Publications, Washington, D.C.1984
• Legionella, Proceedings of the Second Inter­national Symposium on Legionella 
  Chapter: Nosocomial Le­gionnaires' disease: Difference in attack rates associated with two strains of Legionella pneumophila serogroup l 
  Plouffe JF, Para MF, Hackman B, Webster L, Maher WEEditors: Thornsberry C, Balows, Feeley JC, Jakubowski W.ASM Publications, Washington, D.C.1984
• Legionella, Proceedings of the Second Inter­national Symposium on Legionella 
  Chapter: Plasmid profiles of clinical and environmental isolates of serogroup 1 Legionella pneumophila 
  Maher WE, Plouffe JF, Para MFEditors: Thornsberry C, Balows A, Feeley JC, Jakubowski W.ASM Publications, Washington, D.C.1984
• Les Infections 
  Chapter: Chapter 29: Encephalitis and parameningeal infection 
  Para MF, and Gardner PEditors: Jean-Claude Pechere.Edisem, St. Hyacinthe, Quebec1983
• Recent Advances in Clinical Therapeutics: Antivirals and Antimicrobials, Anticancer Agents 
  Chapter: Chapter 4: Newer antiviral agents 
  Para MFGrune & Stratton, Inc., San Diego, CA1983
• The Human Herpesviruses: Interdisciplinary perspective 
  Chapter: The Fc binding receptor induced by herpes simplex virus 
  Spear PG, Para MF, Baucke REditors: A.J. Nahmias, W.R. Dowdle, R. Schinazi.Elsevier North Holland, Inc.1981
• Join now to see all

Lectures

• Computer Assisted Instruction - AIDS: Vignettes for Dental Professionals, Four Case Presentations 
  1/1/1991

Other

• Understanding HIV Infection 
  Para MF, Audio Digest, Internal Medicine
  1/19/1990